Transformation to small-cell carcinoma as an acquired resistance mechanism to AZD9291: A case report

AZD9291, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), benefits patients with T790M mutant non-small-cell lung cancer who fail treatment with first-generation EGFR TKIs. Acquisition of resistance to AZD9291 occurs inevitable and mechanisms need to be exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Wang, Hui, Li, Chao, Wang, Zheng, Zhang, Ping, Yan, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392352/
https://www.ncbi.nlm.nih.gov/pubmed/28061471
http://dx.doi.org/10.18632/oncotarget.14506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392352/
https://www.ncbi.nlm.nih.gov/pubmed/28061471
http://dx.doi.org/10.18632/oncotarget.14506

Ejemplares similares